Nivolumab plus chemotherapy improves leukemia patients’ survival
2 minute read | Published January 12, 2017
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on January 12, 2017
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to preliminary findings by MD Anderson researchers.
The results were from a Phase IB/II ongoing study that paired nivolumab with azacitidine (AZA) in patients who had previously demonstrated poor complete response and overall survival.
“The combination of AZA and nivolumab showed a response rate of 34 percent that compares favorably to a historic response rate of 12 to 15 percent with AZA alone,” said Naval Daver, M.D., assistant professor of Leukemia. “The median overall survival also improved in comparison to historical medians with AZA alone, but longer follow-up is required to confirm the durability and overall survival benefit that could be obtained.”
The study, which followed 51 patients with an average age of 69, also reported side effects in 25 to 30 percent of patients, with the most common being pneumonitis, colitis, skin rash and elevated liver enzymes, all of which were managed with early recognition and systemic steroids. Median overall survival for patients treated with AZA and nivolumab was 9.3 months compared with a historic median of 4.7 months for patients treated with AZA alone.
“We are working closely with colleagues in MD Anderson’s immunotherapy platform to interrogate baseline and on treatment biomarkers of response and to identify additional targetable checkpoints in AML and myelodysplastic syndrome,” said Daver. “We hope these immune checkpoint approaches will be an additional tool to improve outcomes in leukemia patients.”
